SCHEMBL6354674

SCHEMBL6354674

O=C1Nc2ccccc2/C1=C1\C=Cc2cc(OCCBr)ccc2N1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MDM2 Q00987 1/20 0.40
MAOB P27338 9/20 0.39
MAOA P21397 8/20 0.39
MAPT P10636 2/20 0.37
SMN1; SMN2 Q16637 2/20 0.37
ALDH1A1 P00352 1/20 0.37
NPC1 O15118 1/20 0.33
RAB9A P51151 1/20 0.33
PDGFRA P16234 1/20 0.33
FER P16591 1/20 0.33
LTK P29376 1/20 0.33
CDK8 P49336 1/20 0.33
ACVR1 Q04771 1/20 0.33
LRRK2 Q5S007 1/20 0.33
DYRK1B Q9Y463 1/20 0.33
NTRK1 P04629 1/20 0.33
CCNA2 P20248 1/20 0.33
CDK2 P24941 1/20 0.33
CCNA1 P78396 1/20 0.33
CSNK1G1 Q9HCP0 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6354675 1.00 MDM2 (0.40) MDM2MAOBMAOAMAPTSMN1; SMN2
SCHEMBL6353249 0.83 PTPN7 (0.42) MAOBMAOAMAPTSMN1; SMN2ALDH1A1
SCHEMBL6353252 0.83 PTPN7 (0.42) MAOBMAOAMAPTSMN1; SMN2ALDH1A1
SCHEMBL1250660 0.81 FLT3 (0.50) ALDH1A1NPC1RAB9APDGFRALRRK2
SCHEMBL1250665 0.81 FLT3 (0.50) ALDH1A1NPC1RAB9APDGFRALRRK2
SCHEMBL6355225 0.81 ALDH1A1 (0.41) MDM2MAOBMAOAMAPTSMN1; SMN2
SCHEMBL6355223 0.81 ALDH1A1 (0.41) MDM2MAOBMAOAMAPTSMN1; SMN2
SCHEMBL6352911 0.80 MDM2 (0.36) MDM2MAOBMAOAMAPTSMN1; SMN2
SCHEMBL6352914 0.80 MDM2 (0.36) MDM2MAOBMAOAMAPTSMN1; SMN2
SCHEMBL6353679 0.79 MDM2 (0.33) MDM2MAOBMAOAMAPTSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050090498-A1 3-Quinolin-2(1h)-ylideneindolin-2-one derivative YAMANOUCHI PHARMACEUTICAL CO., LTD. (JP) 2005-04-28 US disclosed
EP-1396490-A1 3-QUINOLINE-2-(1H)-YLIDENEINDOLIN-2-ONE DERIVATIVES YAMANOUCHI PHARMACEUTICAL CO. LTD. (JP) 2004-03-10 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050090498-A1 3-Quinolin-2(1h)-ylideneindolin-2-one derivative KDR, FLT4, FLT1 MDM2 801/4885MAOB 4555/4885MAOA 4445/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.